Radiopharm Theranostics (RDPTF) Liabilities and Shareholders Equity (2024 - 2026)

Radiopharm Theranostics (RDPTF) has reported Liabilities and Shareholders Equity for 3 consecutive years, with $426559.5 the latest figure, recorded in Q2 2026.

• On a quarterly basis, Liabilities and Shareholders Equity fell 22.98% year-over-year to $426559.5 in Q2 2026; TTM through Jun 2026 was $93.9 million, a 0.46% change from a year earlier, with the FY2026 full-year figure at $408403.1, down 99.53% from the prior year.
• Liabilities and Shareholders Equity was $426559.5 for Q2 2026 at Radiopharm Theranostics, down from $553858.6 in the prior quarter.
• Over five years, Liabilities and Shareholders Equity peaked at $92.5 million in Q4 2024 and troughed at $426559.5 in Q2 2026.
• A 3-year average of $23.5 million and a median of $514297.9 in 2024 frame the typical range for Liabilities and Shareholders Equity.
• Across the five-year window, Liabilities and Shareholders Equity gained 16.67% in 2025 and decreased 22.98% in 2026, its largest moves.
• Over 3 years, Liabilities and Shareholders Equity stood at $92.5 million in 2024, then sank by 99.4% to $553858.6 in 2025, then decreased by 22.98% to $426559.5 in 2026.
• The last three Liabilities and Shareholders Equity figures came in at $426559.5 (Q2 2026), $553858.6 (Q2 2025), and $92.5 million (Q4 2024), per Business Quant data.